It acts by blocking the transcriptional activity of ER, by impeding AF1 and AF2 thereby reducing the half-life of ER and is termed a selective ER downregulator/degrader (SERD) and is as effective as anastrozole4 in the treatment of ER+ advanced BC. The gene discussed is ESR1; the disease is breast cancer.